Figures
Abstract
Prostaglandins are thought to be important mediators in the initiation of human labour, however the evidence supporting this is not entirely clear. Determining how, and which, prostaglandins change during pregnancy and labour may provide insight into mechanisms governing labour initiation and the potential to predict timing of labour onset. The current study systematically searched the existing scientific literature to determine how biofluid levels of prostaglandins change throughout pregnancy before and during labour, and whether prostaglandins and/or their metabolites may be useful for prediction of labour. The databases EMBASE and MEDLINE were searched for English-language articles on prostaglandins measured in plasma, serum, amniotic fluid, or urine during pregnancy and/or spontaneous labour. Studies were assessed for quality and risk of bias and a qualitative summary of included studies was generated. Our review identified 83 studies published between 1968–2021 that met the inclusion criteria. As measured in amniotic fluid, levels of PGE2, along with PGF2α and its metabolite 13,14-dihydro-15-keto-PGF2α were reported higher in labour compared to non-labour. In blood, only 13,14-dihydro-15-keto-PGF2α was reported higher in labour. Additionally, PGF2α, PGF1α, and PGE2 were reported to increase in amniotic fluid as pregnancy progressed, though this pattern was not consistent in plasma. Overall, the evidence supporting changes in prostaglandin levels in these biofluids remains unclear. An important limitation is the lack of data on the complexity of the prostaglandin pathway outside of the PGE and PGF families. Future studies using new methodologies capable of co-assessing multiple prostaglandins and metabolites, in large, well-defined populations, will help provide more insight as to the identification of exactly which prostaglandins and/or metabolites consistently change with labour. Revisiting and revising our understanding of the prostaglandins may provide better targets for clinical monitoring of pregnancies. This study was supported by the Canadian Institutes of Health Research.
Citation: Wood EM, Hornaday KK, Slater DM (2021) Prostaglandins in biofluids in pregnancy and labour: A systematic review. PLoS ONE 16(11): e0260115. https://doi.org/10.1371/journal.pone.0260115
Editor: Tamas Zakar, John Hunter Hospital, AUSTRALIA
Received: August 27, 2021; Accepted: November 2, 2021; Published: November 18, 2021
Copyright: © 2021 Wood et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting information files.
Funding: This study was supported by the Canadian Institutes of Health Research (CIHR) to DMS (CIHR grant PJT-173295), a University of Calgary, Eye’s High Doctoral Recruitment Scholarship to KKH and an NSERC Undergraduate Student Research Award to EMW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
It is widely believed that prostaglandins are important in the initiation of human labour [1]. Multiple studies have documented increased expression of cyclooxygenases, key enzymes in prostaglandin synthesis, in gestational tissues with the onset of labour, however, this has not been consistently observed [2]. Additionally, prostaglandins are present in maternal blood, urine, and amniotic fluid during pregnancy [3], however, the evidence supporting or refuting their role in labour is conflicting. Prostaglandins are known to affect uterine contractility and cervical ripening [4] and have thus been successfully used for labour induction since the late 1960’s, though the use of prostaglandin synthesis inhibitors for prevention of preterm birth has been minimally successful and is associated with various fetal side effects [5]. Since their discovery in the 1930s, prostaglandins and their synthesis and metabolism are now known to be highly complex, which may contribute to these inconsistent outcomes seen during clinical targeting of this pathway. Aside from providing insight into labour processes, the presence of prostaglandins in peripheral tissues offers the potential for minimally invasive early prediction of labour onset and the ability to distinguish between true and false labour, which remains an ongoing clinical challenge [6]. Additionally, it has been suggested that biomarkers predictive of term labour (>37 weeks gestation) may also be useful for prediction of preterm labour (<37 weeks gestation), as both processes share common physiological changes involving cervical ripening, uterine contractions, and membrane rupture [7]. In 2010, preterm birth was estimated to occur in approximately 11% of all pregnancies and remains the leading cause of neonatal mortality worldwide [8], yet there is a lack of objective measures available to assess risk of premature delivery. Accurate prediction of term and preterm labour would allow for more informed patient planning and more efficient use of healthcare resources, for example, by reducing unnecessary hospitalizations and interventions. Despite evidence to suggest a role for prostaglandins in pregnancy and labour, literature defining the complexities of the pathway remain inconclusive and inconsistent. Therefore, we have systematically reviewed the scientific literature with the aim of answering three main questions to find evidence that either supports or refutes a role for prostaglandins in the initiation of labour: 1) Are prostaglandins or their metabolites detectable in biofluids in higher amounts in labour vs not in labour? 2) Are prostaglandins or their metabolites detected in increasing amounts prior to the onset of labour? And 3) Are prostaglandins or their metabolites present in urine, blood, or amniotic fluid predictive of preterm labour?
Methods
This systematic review was conducted and reported following the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA). The protocol is available upon request. This review was not registered.
Information sources
The databases MEDLINE and EMBASE were searched for records. Additionally, the reference lists of eligible studies and relevant review articles were manually searched.
Search strategy
The search strategy included the key words “prostaglandins” AND “obstetric labor” AND (“amniotic fluid” OR “blood” OR “urine”) as well as synonyms, related alternatives, and Medical Subject Heading (MeSH) terms as relevant. The searches were limited to human studies. Full details of the search terms for each database are given in S1 and S2 Tables. Citations retrieved from the initial search were downloaded into a reference manager (EndNote X9) and duplicates were removed. Two reviewers (EW and SLW) independently reviewed abstracts and removed those not relevant to the research questions. Following retrieval of full-text articles, both reviewers assessed the remaining citations against the eligibility criteria. Studies excluded at this level were sorted based on reason for exclusion. Disagreements were resolved by discussion until consensus was reached.
Inclusion/Exclusion criteria
Primary study journal articles examining endogenous prostaglandins in blood, amniotic fluid, and/or urine during pregnancy and spontaneous labour were included in this review. Studies were excluded if the study was on animals, the study was examining exogenous prostaglandins for induction of labour or if participants experienced spontaneous abortion (prior to 20 weeks). As well, studies which only had samples collected following delivery were excluded. Publications with incomplete information (i.e., conference abstracts) were excluded. Only studies written in English or with an available English translation were included. The search did not include a time restriction, however, the databases MEDLINE and EMBASE include literature published since 1946 and 1947 respectively. The search was initially conducted on May 19, 2020 and was repeated on August 20, 2021.
Selection process/Data extraction
The following information was extracted by one reviewer (EW) from each of the final selected studies: population examined, sample number, type of biofluid collected, method of testing and measurement, metabolites/prostaglandins measured, time of sample collection, country of study origin, available measures of central tendency and variance, and major findings of the study.
Quality assessment
Studies were assessed for quality and risk of bias using a quality assessment tool (Table 1) adapted from Hadley et al. [9] for assessment of basic science research. Full details of the rubric can be found in Table 1. Studies were scored between 0–9. All studies were scored independently by two investigators (EW and KH) and disagreements in scores were resolved by discussion.
Results
Studies identified
The electronic search returned 2257 unique records after removal of duplicates from 2688 records. 2101 records were removed at the title/abstract level, leaving 156 records for assessment at the full-text level. Hand search of reference lists yielded an additional 35 records for review, resulting in a total of 191 full text records. Of the records assessed at the full text level, 108 were excluded, leaving n = 83 studies for inclusion in this review (Fig 1).
Abbreviations: PG = prostaglandin, IOL = induction of labour.
Main characteristics of studies
Summaries of the main characteristics and relevant findings of the included studies can be found in Table 2 (presented in chronological order). Of the 83 studies, most assessed only one biofluid, (34 plasma, 32 amniotic fluid, 8 urine, 4 serum) while 6 studies assessed multiple biofluids. The range of prostaglandins and metabolites investigated included PGF2α, PGF1α, 13,14-dihydro-15-keto-PGF2α (PGFM), 5α,7α-dihydroxy-11-keto-tetranor-prostane-1,16-dioic acid (t-PGFM), PGE1, PGE2, 15-keto-PGE2, 13,14-dihydro-15-keto-PGE2 (PGEM), 11-deoxy-13,14-dihydro-15-keto-11,16-bicyclo-PGE2 (bicyclo-PGEM), 6-keto-PGF1α, 2,3-dinor-6-keto-PGF1α, PGA2, PGD2, PGJ2, 19-OH-PGE2, and 9α,11β-PGF2. Prostaglandins and the corresponding metabolites measured are described in Fig 2. In addition, many older studies used measurement techniques which were unable to differentiate between subcategories of prostaglandins and therefore reported levels of PGE or PGF. The range of prostaglandin concentrations reported using different measurement techniques are shown in Table 3.
n denotes the number of studies that measured the prostaglandin/metabolite. Abbreviations: AF = amniotic fluid, PL = plasma, UR = urine, SE = serum, COX 1/2 = cyclooxygenase 1/2, PGFM = 13,14-dihydro-15-keto-PGF2α, PGEM = 13,14-dihydro-15-keto-PGE2, bicyclo-PGEM = 11-deoxy-13,14-dihydro-15-keto-11,16-bicyclo PGE2, t-PGFM = 5α,7α-dihydroxy-11-keto tetranor-prostane-1,16-dioic acid.
Amniotic fluid
Labour and non-labour.
In total, 25 studies compared amniotic fluid prostaglandins in labour vs non-labour. PGF2α increased in labouring participants compared to non-labouring participants in most studies, (Table 2) however, one study found no difference [69]. Similarly, PGE2 was reported to increase with labour in 11/12 studies [16, 26, 30, 66, 78–80, 82, 87, 91, 92]. 6-keto-PGF1α and PGFM and were reported to increase in labouring participants compared to non-labouring participants in three [40, 79, 80] and seven [32, 41, 78–80, 87, 91] studies, respectively. Results were mixed for PGE1 [26, 33]. PGE was not found to increase with labour [29, 69].
Prior to labour onset.
Of the included amniotic fluid studies, 15 measured prostaglandins at more than one time point throughout pregnancy. PGF2α, PGF1α, and PGF were generally found to increase around term or prior to labour [17, 22, 27, 28, 30, 37, 52, 82, 85], though two studies found no pattern throughout pregnancy [26, 33]. Among studies that measured PGE or PGE2, most (4/6) reported increased levels around 35–36 weeks [30, 37, 52, 85]. PGE1 was not found to change with gestational age [26, 30, 33].
Predicting preterm labour.
Six amniotic fluid studies investigated prostaglandins as predictors of preterm labour. Some studies suggest that PGF2α may be predictive of preterm delivery in those with threatened preterm labour [88] and PPROM [86] however, results are mixed [71, 73]. PGFM and bicyclo-PGEM were found in higher levels in participants with preterm labour leading to preterm delivery compared to those who eventually delivered at term [71]. Increased PGE2 levels may be predictive of delivery before term [68, 73] and before 34 weeks [76].
Blood
Labour and non-labour.
In total, 27 studies compared labour and non-labour groups. PGF2α was reported to increase with labour compared to non-labour in most (6/8) studies [21, 41, 50, 55, 69, 72]. All 15 studies that measured PGFM reported higher levels in labour compared to non-labour (Table 2). Three studies measuring PGE reported varying results [29, 36, 69]. PGE1, PGE2, and PGF were all generally found to remain unchanged with labour [29, 33, 36, 50, 55].
Prior to labour onset.
In total, 18 studies obtained measurements of plasma throughout pregnancy. Among those that measured PGF2α, some found increasing levels at or near term [37, 50, 60] however results were conflicting [21, 28, 33]. In 5/6 studies PGFM was not found to change with increasing gestational age [39, 41, 43, 44, 58]. Results for PGF2α in serum were mixed [11–13].
Predicting preterm labour.
Two studies investigated prostaglandins in plasma as predictors of preterm labour. One study found that PGFM levels were higher in participants in preterm labour who delivered preterm compared to those who went on to deliver at term [61] though the other study reported no significant difference [44].
Urine
Labour and non-labour.
Five studies compared labouring vs non-labouring groups. The metabolite t-PGFM was reported to increase with labour compared to non-labour [20, 31, 41].
Prior to labour onset.
Four studies measured changes in prostaglandins in urine throughout pregnancy. PGF2α, PGFM, and t-PGFM were reported to increase around term, though this was only reported in one study for each prostaglandin/metabolite [20, 83]. The metabolite 2,3-dinor-6-keto-PGF1α did not change throughout pregnancy [81].
Predicting preterm labour.
Two urine studies investigated prostaglandins as predictors of preterm labour. One found that PGF2α levels in urine samples collected at median 32.1 weeks were not significantly different between participants who delivered at term and those that delivered preterm [89]. In contrast, averaged levels of PGF2α in urine were also found to be associated with increased odds of preterm birth (OR = 1.98) [90].
Serial prostaglandin measurement during spontaneous labour
Although not a primary study question of this review, we noted that n = 40 studies obtained serial samples during labour. In general, prostaglandins measured in amniotic fluid increased throughout labour. Results were mixed for those that measured plasma and serum.
Quality assessment
Scores from the quality assessment were distributed as follows: 17% scored between 0–3, 41% scored between 4–6, and 42% scored between 7–9. The areas with the lowest scores were researcher blinding and sufficiency of sample number for internal validity. Scores for each study can be found in S3 Table.
Discussion
We demonstrate, through a systematic review of the literature investigating prostaglandins and metabolites in peripheral biofluids during pregnancy and labour, that prostaglandins of the PGE and PGF families do exhibit changes through pregnancy and labour, though results are inconsistent and inconclusive. Changes in PGE2, PGF2α, and PGFM levels with labour are most prominent in amniotic fluid, and to a lesser extent in blood. Similarly, our synthesis suggests that PGE2, PGF2α and PGF1α increase in amniotic fluid as pregnancy progresses and peak around term, though in plasma, a consistent pattern is unclear. Patterns in urine prostaglandin levels were inconclusive due to a relatively small number of studies investigating this biofluid. An important limitation is a general lack of data on prostaglandins and metabolites outside the PGE and PGF families, and as such we are unable to comment on their potential role in pregnancy and labour. Further, few studies examined prostaglandins as biomarkers for preterm labour and more research is needed to provide conclusive evidence for which prostaglandins or metabolites examined could offer the best options for prediction.
Measurement techniques for prostaglandins
Inconsistent study designs and methods greatly limited our ability to compare findings across studies. Up to the late 1990’s, researchers most commonly used radioimmunoassay techniques, which can be highly sensitive, but are often limited by the specificity of the antibody used and the potential of antibody cross-reactivity with similar molecules [87]. One study included in this review developed and reported on a radioimmunoassay for PGF2α with a cross-reactivity with PGF1α of 12.2% [17], which may have obscured patterns in PGF2α and made it difficult to ascertain fine-tuning of the prostaglandin pathway among similar molecules. Furthermore, multiple other studies using radioimmunoassay techniques were unable to differentiate between PGF2α and PGF1α, and PGE2 and PGE1 and therefore could only report on levels of PGF and PGE, respectively, making it difficult to compare the results of these studies with others. Lack of specificity and accuracy in these radioimmunoassay techniques may have contributed to the discrepancies across results and highlights the importance of re-visiting dogma in light of novel evidence and technologies. In contrast, the high specificity and sensitivity of mass spectrometry for lipid identification suggests that this method may be more suitable and accurate for measurement of prostaglandins [87]. Additionally, the capability of mass spectrometry to co-assess multiple prostaglandins and metabolites can provide a quantitative profile of prostaglandins before and during labour, as well as identify prostaglandins and/or metabolites not previously measured that may play a role in pregnancy and/or labour [93].
Considerations among unique biofluids
Among the studies included in this review, the most assayed biofluid was maternal plasma. Although an appealing fluid due to its ability to be sampled relatively easily, results from measurements in plasma were often conflicting, especially among studies that measured primary prostaglandins. Accurate measurement of changes in primary prostaglandin levels in blood is complicated by their rapid metabolism and correspondingly short half-life [94, 95]. This difficulty is further compounded by the production of prostaglandins by platelets that occurs during isolation of plasma and storage of samples [36, 96, 97]. Measurement of plasma PGFM appears to be a good alternative for PGF2α, as there is no evidence that this metabolite is formed during sample collection or isolation and therefore may more accurately reflect endogenous prostaglandin production [19]. The primary metabolite of PGE2, however, is chemically unstable [98], which necessitates the measurement of its degradation product, bicyclo-PGEM, for an accurate index of PGE2 production [99]. Therefore, results from early studies measuring primary prostaglandins and/or PGEM in plasma and/or serum should be interpreted with these considerations in mind and future studies in blood should aim to measure PGFM or bicyclo-PGEM as indices of PGF2α or PGE2 production, respectively.
Amniotic fluid lacks prostaglandin metabolizing enzymes [100, 101], which suggests that measurement of the primary prostaglandins in this fluid may be more accurate than in serum or plasma. However, sampling amniotic fluid is more difficult and may introduce infections harmful to the developing fetus, making this fluid impractical as a predictive resource. Additionally, prostaglandin levels vary based on method of collection and region of the amniotic sac [102, 103] which complicates any interpretation of results from studies and limits the clinical utility of an amniotic fluid test for prediction of preterm labour.
Measurement of the main urinary metabolite of PGF2α may be preferable to measuring PGFM in plasma or serum in some cases, as a significant portion of circulating PGF2α is eventually excreted into the urine [104]. In the present investigation, we identified only nine studies that assayed urine, and we suggest that the presence of urinary metabolites of prostaglandins during pregnancy and labour merits further study.
Demographic and clinical information
Among the articles included in this review, we noted that very few provided complete demographic and clinical information on their participants. Factors including age, race/ethnicity, membrane status, and gravidity/parity may impact prostaglandins levels and a lack of consideration for these variables may obscure patterns of prostaglandin levels throughout pregnancy and labour. Complete descriptions of gestational age groups and clearly defined outcomes for both term and preterm labour would additionally make studies more easily comparable. As well, preterm labour is generally defined as labour occurring before 37 weeks gestation, however the pathophysiological processes involved in extreme preterm birth (<28 weeks) may vary dramatically from those near term [105]. Therefore, stratification of outcome groups based on gestational age at delivery may be more informative, though would require larger sample sizes to maintain statistical power.
Role for other prostaglandins
While prostaglandins of the E and F series are most clinically targeted for labour management, there is evidence to suggest that other members of the prostaglandin family may play a role in pregnancy and labour. For example, PGD2 has been shown to increase uterine contractility and blood flow in various mammals [106–108] and is associated with cervical dilation in humans [63]. Two metabolites of PGD2, 9α,11β-PGF2 and PGJ2, were each identified only once among the articles included in this review and were both reported to increase with term labour [84, 87]. These metabolites may be of interest to future researchers, as the development of new methodologies such as mass spectrometry have allowed for more accurate and sensitive measurements of select members of the prostaglandin pathway.
Conclusion
We have identified evidence to suggest that prostaglandin levels, particularly within the PGE and PGF families, do increase in some biofluids during pregnancy and labour. However, changing prostaglandin levels throughout pregnancy and labour are likely highly complex and warrant further investigation, including serial measurements with more precise methodologies in higher-powered studies. Two important limitations identified in this review are the lack of data on the complexity of the prostaglandin pathway outside of the PGE and PGF families and the inherent difficulty in measuring primary prostaglandins in blood, due to their short half-lives in this biofluid. With the advent of i) new methodologies that can assess multiple prostaglandins and metabolites together, ii) a more developed understanding of the range of prostaglandins and iii) a better understanding of the heterogeneous nature of term and preterm labour, future studies that take each of these parameters into account in their study design will help provide further insight into the changing levels of prostaglandins in pregnancy and labour.
References
- 1. Challis JR, Sloboda DM, Alfaidy N, Lye SJ, Gibb W, Patel FA, et al. Prostaglandins and mechanisms of preterm birth. Reproduction. 2002;124(1):1–17. pmid:12090913
- 2. Urrego D, Liwa AC, Cole WC, Wood SL, Slater DM. Cyclooxygenase inhibitors for treating preterm labour: What is the molecular evidence? Can J Physiol Pharmacol. 2019;97(3):222–31. pmid:30661374
- 3. Green K. Determination of prostaglandins in body fluids and tissues. Acta Obstet Gynecol Scand Suppl. 1979;87:15–20. pmid:288293
- 4. Olson DM. The role of prostaglandins in the initiation of parturition. Best Pract Res Clin Obstet Gynaecol. 2003;17(5):717–30. pmid:12972010
- 5. Reinebrant HE, Pileggi-Castro C, Romero CLT, Dos Santos RAN, Kumar S, Souza JP, et al. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev. 2015;2015(6):CD001992–CD. pmid:26042617
- 6. Schlembach D, Maner WL, Garfield RE, Maul H. Monitoring the progress of pregnancy and labor using electromyography. Eur J Obstet Gynecol Reprod Biol. 2009;144 Suppl 1:S33–9. pmid:19278772
- 7. Heng YJ, Liong S, Permezel M, Rice GE, Di Quinzio MK, Georgiou HM. The interplay of the interleukin 1 system in pregnancy and labor. Reprod Sci. 2014;21(1):122–30. pmid:23749763
- 8. Vogel JP, Chawanpaiboon S, Moller AB, Watananirun K, Bonet M, Lumbiganon P. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol. 2018;52:3–12. pmid:29779863
- 9. Hadley EE, Richardson LS, Torloni MR, Menon R. Gestational tissue inflammatory biomarkers at term labor: A systematic review of literature. Am J Reprod Immunol. 2018;79(2): pmid:29076197
- 10. Karim SM. Appearance of prostaglandin F2-alpha in human blood during labour. Br Med J. 1968;4(5631):618–21. pmid:5723366
- 11. Brummer HC. Serum PGF2 alpha levels during late pregnancy, labour and the puerperium. Prostaglandins. 1972;2(3):185–94. pmid:4653733
- 12. Gutierrez-Cernosek RM, Zuckerman J, Levine L. Prostaglandin F2alpha levels in sera during human pregnancy. Prostaglandins. 1972;1(4):331–7. pmid:4676641
- 13. Brummer HC. Serum PGF2alpha levels during human pregnancy. Prostaglandins. 1973;3(1):3–5. pmid:4693718
- 14. Brummer HC, Craft IL. Prostaglandin F2alpha and labour. Acta Obstet Gynecol Scand. 1973;52(3):273–5. pmid:4743782
- 15. Hertelendy F, Woods R, Jaffe BM. Prostaglandin E levels in peripheral blood during labor. Prostaglandins. 1973;3(2):223–7. pmid:4729571
- 16. Keirse MJ, Turnbull AC. E prostaglandins in amniotic fluid during late pregnancy and labour. J Obstet Gynaecol Br Commonw. 1973;80(11):970–3. pmid:4752988
- 17. Salmon JA, Amy J-J. Levels of prostaglandin F2α in amniotic fluid during pregnancy and labour. Prostaglandins. 1973;4(4):523–33.
- 18. Challis JR, Osathanondh R, Ryan KJ, Tulchinsky D. Maternal and fetal plasma prostaglandin levels at vaginal delivery and cesarean section. Prostaglandins. 1974;6(4):281–8. pmid:4853104
- 19. Green K, Bygdeman M, Toppozada M, Wiqvist N. The role of prostaglandin F2alpha in human parturition. Endogenous plasma levels of 15-keto-13,14-dihydro-prostaglandin F2alpha during labor. Am J Obstet Gynecol. 1974;120(1):25–31. pmid:4846168
- 20. Hamberg M. Quantitative studies on prostaglandin synthesis in man III. Excretion of the major urinary metabolite of prostaglandins F1α and F2α during pregnancy. Life Sci. 1974;14(2):247–52. pmid:4813589
- 21. Hennam JF, Johnson DA, Newton JR, Collins WP. Radioimmunoassay of prostaglandin F-2-alpha in peripheral venous plasma from men and women. Prostaglandins. 1974;5(6):531–42. pmid:4856639
- 22. Hibbard BM, Sharma SC, Fitzpatrick RJ, Hamlett JD. Prostaglandin F2alpha concentrations in amniotic fluid in late pregnancy. J Obstet Gynaecol Br Commonw. 1974;81(1):35–8. pmid:4818314
- 23. Hillier K, Calder AA, Embrey MP. Concentrations of prostaglandin F2alpha in amniotic fluid and plasma in spontaneous and induced labours. The Journal of obstetrics and gynaecology of the British Commonwealth. 1974;81(4):257–63. pmid:4824681
- 24. Keirse MJ, Flint AP, Turnbull AC. F prostaglandins in amniotic fluid during pregnancy and labour. J Obstet Gynaecol Br Commonw. 1974;81(2):131–5. pmid:4816023
- 25. MacDonald PC, Schultz FM, Duenhoelter JH, Gant NF, Jimenez JM, Pritchard JA, et al. Initiation of human parturition. I. Mechanism of action of arachidonic acid. Obstet Gynecol. 1974;44(5):629–36. pmid:4420973
- 26. Singh EJ, Zuspan FP. Content of amniotic fluid prostaglandins in normal, diabetic, and drug-abuse human pregnancy. Am J Obstet Gynecol. 1974;118(3):358–61. pmid:4810040
- 27. Hillier K, Calder AA, MacKenzie IZ. Proceedings: Prostaglandin F alpha in amniotic fluid in man. J Endocrinol. 1975;64(1):13P. pmid:1167892
- 28. Johnson DA, Manning PA, Hennam JF, Newton JR, Collins WP. The concentration of prostaglandin f2alpha in maternal plasma, foetal plasma and amniotic fluid during pregnancy in women. Acta Endocrinol. 1975;79(3):589–97. pmid:1173509
- 29. Pokoly TB, Jordan VC. Relation of steroids and prostaglandin at vaginal delivery and cesarean section. Obstet Gynecol. 1975;46(5):577–80. pmid:1196562
- 30. Dray F, Frydman R. Primary prostaglandins in amniotic fluid in pregnancy and spontaneous labor. Am J Obstet Gynecol. 1976;126(1):13–9. pmid:961739
- 31. Granstrom E, Kindahl H. Radioimmunoassay for urinary metabolites of prostaglandin F2alpha. Prostaglandins. 1976;12(5):759–83. pmid:981701
- 32. Keirse MJ, Mitchell MD, Turnbull AC. Changes in prostaglandin F and 13,14-dihydro-15-keto-prostaglandin F concentrations in amniotic fluid at the onset of and during labour. Br J Obstet Gynaecol. 1977;84(10):743–6. pmid:921911
- 33. Kinoshita K, Satoh K, Sakamoto S. Prostaglandin F2alpha and E1 in plasma and amniotic fluid during human pregnancy and labor. Endocrinol Jpn. 1977;24(2):155–62. pmid:872820
- 34. TambyRaja RL, Salmon JA, Karim SM, Ratnam SS. F prostaglandin levels in amniotic fluid in premature labour. Prostaglandins. 1977;13(2):339–48. pmid:847237
- 35. Haning RV Jr., Barrett DA, Alberino SP, Lynskey MT, Donabedian R, Speroff L. Interrelationships between maternal and cord prolactin, progesterone, estradiol, 13,14-dihydro-15-keto-prostaglandin F2alpha, and cord cortisol at delivery with respect to initiation of parturition. Am J Obstet Gynecol. 1978;130(2):204–10. pmid:563675
- 36. Mitchell MD, Flint AP, Bibby J, Brunt J, Arnold JM, Anderson AB, et al. Plasma concentrations of prostaglandins during late human pregnancy: influence of normal and preterm labor. J Clin Endocrinol Metab. 1978;46(6):947–51. pmid:263475
- 37. Nieder J, Augustin W. Investigations on prostaglandin levels in amniotic fluid and maternal blood during late pregnancy. Acta Biol Med Ger. 1978;37(5–6):945–7. pmid:742318
- 38. Zuckerman H, Reiss U, Atad J, Lampert I, Ezra SB, Sklan D. Prostaglandin F2alpha human blood during labor. Obstet Gynecol. 1978;51(3):311–4. pmid:628533
- 39. Ghodgaonkar RB, Dubin NH, Blake DA, King TM. 13, 14-dihydro-15-keto-prostaglandin F2alpha concentrations in human plasma and amniotic fluid. Am J Obstet Gynecol. 1979;134(3):265–9. pmid:453260
- 40. Mitchell MD, Keirse MJ, Brunt JD, Anderson AB, Turnbull AC. Concentrations of the prostacyclin metabolite, 6-keto-prostaglandin F1 alpha, in amniotic fluid during late pregnancy and labour. Br J Obstet Gynaecol. 1979;86(5):350–3. pmid:380629
- 41. Satoh K, Yasumizu T, Fukuoka H, Kinoshita K, Kaneko Y, Tsuchiya M, et al. Prostaglandin F2 alpha metabolite levels in plasma, amniotic fluid, and urine during pregnancy and labor. Am J Obstet Gynecol. 1979;133(8):886–90. pmid:434032
- 42. Lewis PJ, Boylan P, Friedman LA, Hensby CN, Downing I. Prostacyclin in pregnancy. Br Med J. 1980;280(6231):1581–2. pmid:7000245
- 43. Dubin NH, Johnson JW, Calhoun S, Ghodgaonkar RB, Beck JC. Plasma prostaglandin in pregnant women with term and preterm deliveries. Obstet Gynecol. 1981;57(2):203–6. pmid:7465125
- 44. Sellers SM, Mitchell MD, Bibby JG, Anderson AB, Turnbull AC. A comparison of plasma prostaglandin levels in term and preterm labour. Br J Obstet Gynaecol. 1981;88(4):362–6. pmid:7225293
- 45. Ylikorkala O, Makarainen L, Viinikka L. Prostacyclin production increases during human parturition. Br J Obstet Gynaecol. 1981;88(5):513–6. pmid:7016168
- 46. Fuchs A-R, Husslein P, Sumulong L, Fuchs F. The origin of circulating 13,14-dihydro-15-keto-prostaglandin F2α during delivery. Prostaglandins. 1982;24(5):715–22. pmid:7163513
- 47. Fuchs AR, Husslein P, Sumulong L, Micha JP, Dawood MY, Fuchs F. Plasma levels of oxytocin and 13, 14-dihydro-15-keto prostaglandin F2 alpha in preterm labor and the effect of ethanol and ritodrine. Am J Obstet Gynecol. 1982;144(7):753–9. pmid:7148897
- 48. Mitchell MD, Ebenhack K, Kraemer DL, Cox K, Cutrer S, Strickland DM. A sensitive radioimmunoassay for 11-deoxy-13, 14-dihydro-15-keto-11, 16-cyclo-prostaglandin E2: application as an index of prostaglandin E2 biosynthesis during human pregnancy and parturition. Prostaglandins Leukot Med. 1982;9(5):549–57. pmid:6960378
- 49. Sellers SM, Hodgson HT, Mitchell MD, Anderson ABM, Turnbull AC. Raised prostaglandin levels in the third stage of labor. Am J Obstet Gynecol. 1982;144(2):209–12. pmid:7114131
- 50. Sharma SC, Walzman M, Molloy A, Bonnar J. Relationship of total ascorbic acid to prostaglandins F2 alpha and E2 levels in the blood of women during the 3rd trimester of normal pregnancy. Int J Vitam Nutr Res. 1982;52(3):312–9. pmid:6959982
- 51. Fuchs AR, Goeschen K, Husslein P, Rasmussen AB, Fuchs F. Oxytocin and the initiation of human parturition III. Plasma concentrations of oxytocin and 13,14-dihydro-15-keto-prostaglandin F2alpha in spontaneous and oxytocin-induced labor at term. Am J Obstet Gynecol. 1983;147(5):497–502. pmid:6638091
- 52. Nieder J, Augustin W. Increase of prostaglandin E and F equivalents in amniotic fluid during late pregnancy and rapid PG F elevation after cervical dilatation. Prostaglandins Leukot Med. 1983;12(3):289–97. pmid:6581485
- 53. Spitz B, Deckmyn H, Van Assche FA, Vermylen J. Prostacyclin production in whole blood throughout normal pregnancy. Clin Exp Hypertens B. 1983;2(2):191–202. pmid:6347442
- 54. Husslein P, Sinzinger H. Concentration of 13,14-dihydro-15-keto-prostaglandin E2 in the maternal peripheral plasma during labour of spontaneous onset. Br J Obstet Gynaecol. 1984;91(3):228–31. pmid:6704346
- 55. Nagata I, Kato K, Makimura N, Furuya K. Differences in human plasma oxytocin, prostaglandin E1, E2 and F2 alpha levels between spontaneous and amniotomy-induced labors. Asia Oceania J Obstet Gynaecol. 1984;10(4):513–20. pmid:6598029
- 56. Reddi K, Kambaran SR, Norman RJ, Joubert SM, Philpott RH. Abnormal concentrations of prostaglandins in amniotic fluid during delayed labour in multigravid patients. Br J Obstet Gynaecol. 1984;91(8):781–7. pmid:6590093
- 57. Sellers SM, Mitchell MD, Anderson AB, Turnbull AC. The influence of spontaneous and induced labour on the rise in prostaglandins at amniotomy. Br J Obstet Gynaecol. 1984;91(9):849–52. pmid:6591948
- 58. Yamaguchi M, Mori N. 6-Keto prostaglandin F1 alpha, thromboxane B2 and 13,14-dihydro-15-keto prostaglandin F levels in maternal and fetal plasma. Prostaglandins Leukot Med. 1984;15(3):325–36. pmid:6593746
- 59. Brennecke SP, Castle BM, Demers LM, Turnbull AC. Maternal plasma prostaglandin E2 metabolite levels during human pregnancy and parturition. Br J Obstet Gynaecol. 1985;92(4):345–9. pmid:3857076
- 60. Ogino M, Jimbo T. Comparison of plasma prostaglandins in the non-pregnant and pregnant women: a longitudinal study. Nihon Sanka Fujinka Gakkai Zasshi. 1986;38(7):1120–4. pmid:3462267
- 61. Weitz CM, Ghodgaonkar RB, Dubin NH, Niebyl JR. Prostaglandin F metabolite concentration as a prognostic factor in preterm labor. Obstet Gynecol. 1986;67(4):496–9. pmid:3457328
- 62. Ylikorkala O, Paatero H, Suhonen L, Viinikka L. Vaginal and abdominal delivery increases maternal urinary 6-keto-prostaglandin F(1alpha) excretion. Br J Obstet Gynaecol. 1986;93(9):950–4. pmid:3768289
- 63. Berryman GK, Strickland DM, Hankins GD, Mitchell MD. Amniotic fluid prostaglandin D2 in spontaneous and augmented labor. Life Sci. 1987;41(13):1611–4. pmid:3476816
- 64. Nagata I, Seki K, Uesato T. Changes in plasma oxytocin, prostaglandin E1, and 13,14-dihydro-15-keto-prostaglandin F(2alpha) during labor induced by prostaglandin E2 or F(2alpha) and spontaneous labor. Acta Obstet Gynaecol Jpn. 1987;39(9):1627–33.
- 65. Nagata I, Sunaga H, Furuya K, Makimura N, Kato K. Changes in the plasma prostaglandin F2 alpha metabolite before and during spontaneous labor and labor induced by amniotomy, oxytocin and prostaglandin E2. Endocrinol Jpn. 1987;34(2):153–9. pmid:3476296
- 66. Romero R, Emamian M, Wan M, Quintero R, Hobbins JC, Mitchell MD. Prostaglandin concentrations in amniotic fluid of women with intra-amniotic infection and preterm labor. Am J Obstet Gynecol. 1987;157(6):1461–7. pmid:3480691
- 67. Noort WA, De Zwart FA, Keirse MJNC. Changes in urinary 6-keto-prostaglandin F1(alpha) excretion during pregnancy and labor. Prostaglandins. 1988;35(4):573–82. pmid:3247472
- 68. Romero R, Wu YK, Mazor M, Hobbins JC, Mitchell MD. Amniotic fluid prostaglandin E2 in preterm labor. Prostaglandins Leukot Essent Fatty Acids. 1988;34(3):141–5. pmid:3222272
- 69. Sahmay S, Coke A, Hekim N, Atasu T. Maternal, umbilical, uterine and amniotic prostaglandin E and F2 alpha levels in labour. J Int Med Res. 1988;16(4):280–5. pmid:3169373
- 70. Noort WA, van Bulck B, Vereecken A, de Zwart FA, Keirse MJNC. Changes in plasma of PGF2α and PGI2 metabolites at and after delivery at term. Prostaglandins. 1989;37(1):3–12. pmid:2655010
- 71. Romero R, Wu YK, Sirtori M, Oyarzun E, Mazor M, Hobbins JC, et al. Amniotic fluid concentrations of prostaglandin F2 alpha, 13,14-dihydro-15-keto-prostaglandin F2 alpha (PGFM) and 11-deoxy-13,14-dihydro-15-keto-11, 16-cyclo-prostaglandin E2 (PGEM-LL) in preterm labor. Prostaglandins. 1989;37(1):149–61. pmid:2717777
- 72. Yamamoto K, Kitao M. Interrelation among endogenous catecholamines, prostaglandin F2 alpha and prolactin in last trimester and during parturition. Nippon Sanka Fujinka Gakkai zasshi. 1989;41(9):1479–86. pmid:2555427
- 73. Mazor M, Wiznitzer A, Maymon E, Leiberman JR, Cohen A. Changes in amniotic fluid concentrations of prostaglandins E2 and F2 alpha in women with preterm labor. Isr J Med Sci. 1990;26(8):425–8. pmid:2401604
- 74. Norman RJ, Reddi K. Prostaglandins in dysfunctional labour; evidence for altered production of prostaglandin F2 alpha. Reprod Fertil Dev. 1990;2(5):563–74. pmid:2127461
- 75. Fairlie F, Phillips G, McLaren M, Calder A, Walker J. Uterine activity in spontaneous labour and maternal peripheral plasma prostaglandin E2 and F(2alpha) metabolites. J Perinat Med. 1993;21(1):35–42. pmid:8487148
- 76. Hillier SL, Witkin SS, Krohn MA, Watts DH, Kiviat NB, Eschenbach DA. The relationship of amniotic fluid cytokines and preterm delivery, amniotic fluid infection, histologic chorioamnionitis, and chorioamnion infection. Obstet Gynecol. 1993;81(6):941–8. pmid:8497360
- 77. Johnston TA, Greer IA, Kelly RW, Calder AA. Plasma prostaglandin metabolite concentrations in normal and dysfunctional labour. Br J Obstet Gynaecol. 1993;100(5):483–8. pmid:8518251
- 78. MacDonald PC, Casey ML. The accumulation of prostaglandins (PG) in amniotic fluid is an aftereffect of labor and not indicative of a role for PGE2 or PGF2 alpha in the initiation of human parturition. J Clin Endocrinol Metab. 1993;76(5):1332–9. pmid:8496326
- 79. Romero R, Baumann P, Gomez R, Salafia C, Rittenhouse L, Barberio D, et al. The relationship between spontaneous rupture of membranes, labor, and microbial invasion of the amniotic cavity and amniotic fluid concentrations of prostaglandins and thromboxane B2 in term pregnancy. Am J Obstet Gynecol. 1993;168(6 Pt 1):1654–8. pmid:8317506
- 80. Romero R, Baumann P, Gonzalez R, Gomez R, Rittenhouse L, Behnke E, et al. Amniotic fluid prostanoid concentrations increase early during the course of spontaneous labor at term. Am J Obstet Gynecol. 1994;171(6):1613–20. pmid:7802078
- 81. Lindsay C, Moutquin JM, Gaudreault CR, Forest JC. Development of an enzyme-linked immunosorbent assay for 2,3-dinor-6-keto-prostaglandin F(1alpha) in urine using a monoclonal antibody. Clin Biochem. 1995;28(4):395–400. pmid:8521593
- 82. Romero R, Munoz H, Gomez R, Parra M, Polanco M, Valverde V, et al. Increase in prostaglandin bioavailability precedes the onset of human parturition. Prostaglandins Leukot Essent Fatty Acids. 1996;54(3):187–91. pmid:8860106
- 83. Ichikawa M, Minami M. Correlations between corticotropin-releasing hormone and L-3,4-dihydroxyphenylalanine in plasma, and dopamine and prostaglandins in urine in pregnant mothers. Biog Amines. 1999;15(2):287–306.
- 84. Mitchell MD, Chang MC, Chaiworapongsa T, Lan H-Y, Helliwell RJA, Romero R, et al. Identification of 9alpha,11beta-prostaglandin F2 in human amniotic fluid and characterization of its production by human gestational tissues. J Clin Endocrinol Metab. 2005;90(7):4244–8. pmid:15840748
- 85. Lee SE, Romero R, Park I-S, Seong HS, Park C-W, Yoon BH. Amniotic fluid prostaglandin concentrations increase before the onset of spontaneous labor at term. J Matern Fetal Neonatal Med. 2008;21(2):89–94. pmid:18240075
- 86. Lee SE, Park I-S, Romero R, Yoon BH. Amniotic fluid prostaglandin F2 increases even in sterile amniotic fluid and is an independent predictor of impending delivery in preterm premature rupture of membranes. J Matern Fetal Neonatal Med. 2009;22(10):880–6. pmid:19544157
- 87. Maddipati KR, Romero R, Chaiworapongsa T, Zhou SL, Xu Z, Tarca AL, et al. Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor. FASEB J. 2014;28(11):4835–46. pmid:25059230
- 88. Park JY, Romero R, Lee J, Chaemsaithong P, Chaiyasit N, Yoon BH. An elevated amniotic fluid prostaglandin F2α concentration is associated with intra-amniotic inflammation/infection, and clinical and histologic chorioamnionitis, as well as impending preterm delivery in patients with preterm labor and intact membranes. J Matern Fetal Neonatal Med. 2016;29(16):2563–72. pmid:26669519
- 89. Rosen EM, van ’t Erve TJ, Boss J, Sathyanarayana S, Barrett ES, Nguyen RHN, et al. Urinary oxidative stress biomarkers and accelerated time to spontaneous delivery. Free Rad Biol Med. 2019;130:419–25. pmid:30445128
- 90. Eick SM, Ferguson KK, Milne GL, Rios-McConnell R, Velez-Vega C, Rosario Z, et al. Repeated measures of urinary oxidative stress biomarkers and preterm birth in Puerto Rico. Free Radic Biol Med. 2020;146:299–305. pmid:31704372
- 91. Peiris HN, Romero R, Vaswani K, Gomez-Lopez N, Tarca AL, Gudicha DW, et al. Prostaglandin and prostamide concentrations in amniotic fluid of women with spontaneous labor at term with and without clinical chorioamnionitis. Prostaglandins Leukot Essent Fatty Acids. 2020;163:102195. pmid:33137520
- 92. Takahashi N, Okuno T, Fujii H, Makino S, Takahashi M, Ohba M, et al. Up-regulation of cytosolic prostaglandin E synthase in fetal-membrane and amniotic prostaglandin E2 accumulation in labor. PloS one. 2021;16(4):e0250638–e. pmid:33891661
- 93. Durn JH, Marshall KM, Farrar D, O’Donovan P, Scally AJ, Woodward DF, et al. Lipidomic analysis reveals prostanoid profiles in human term pregnant myometrium. Prostaglandins Leukot Essent Fatty Acids. 2010;82(1):21–6. pmid:19954938
- 94. Hamberg M, Samuelsson B. On the metabolism of prostaglandins E 1 and E 2 in man. J Biol Chem. 1971;246(22):6713–21. pmid:5126221
- 95. Granström E. On the metabolism of prostaglandin F 2 in female subjects. Structures of two metabolites in blood. Eur J Biochem. 1972;27(3):462–9. pmid:5050657
- 96. Jubiz W, Frailey J. Prostaglandin e generation during storage of plasma samples. Prostaglandins. 1974;7(4):339–44. pmid:4415345
- 97. Smith JB, Ingerman C, Kocsis JJ, Silver MJ. Formation of prostaglandins during the aggregation of human blood platelets. J Clin Invest. 1973;52(4):965–9. pmid:4693658
- 98. Granström E, Hamberg M, Hansson G, Kindahl H. Chemical instability of 15-keto-13,14-dihydro-PGE2: the reason for low assay reliability. Prostaglandins. 1980;19(6):933–57. pmid:7384561
- 99. Bothwell W, Verburg M, Wynalda M, Daniels EG, Fitzpatrick FA. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. J Pharmacol Exp Ther. 1982;220(2):229–35. pmid:6948952
- 100. Brennand J, Leask R, Kelly R, Greer I, Calder A. The influence of amniotic fluid on prostaglandin synthesis and metabolism in human fetal membranes. Acta Obstet Gynecol Scand. 1998;77(2):142–50. pmid:9512316
- 101. Keirse MJNC Turnbull AC. METABOLISM OF PROSTAGLANDINS WITHIN THE PREGNANT UTERUS. Br J Obstet Gynaecol. 1975;82(11):887–93. pmid:1191603
- 102. Mitchell MD, Keirse MJ, Anderson AB, Turnbull AC. Evidence for a local control of prostaglandins within the pregnant human uterus. Br J Obstet Gynaecol. 1977;84(1):35–8. pmid:843469
- 103. Romero R, Gonzalez R, Baumann P, Behnke E, Rittenhouse L, Barberio D, et al. Topographic differences in amniotic fluid concentrations of prostanoids in women in spontaneous labor at term. Prostaglandins Leukot Essent Fatty Acids. 1994;50(2):97–104. pmid:8171074
- 104. Granström E. On the metabolism of prostaglandin F 2 in female subjects. Structures of two C 14 metabolites. Eur J Biochem. 1972;25(3):581–9. pmid:5043324
- 105. Ananth CV, Friedman AM, Gyamfi-Bannerman C. Epidemiology of moderate preterm, late preterm and early term delivery. Clin Perinatol. 2013;40(4):601–10. pmid:24182950
- 106. Hu C, Liu B, Li H, Wu X, Guo T, Luo W, et al. Prostaglandin D2 evokes potent uterine contraction via the F prostanoid receptor in postpartum rats. Eur J Pharmacol. 2018;836:11–7. pmid:30107163
- 107. Clark KE, Austin JE, Stys SJ. Effect of bisenoic prostaglandins on the uterine vasculature of the nonpregnant sheep. Prostaglandins. 1981;22(3):333–48. pmid:7029654
- 108. McLaughlin MK, Phernetton TM, Rankin JHG. Prostaglandin D2: Effects on the Rabbit Utero-Placental Circulation. Proc Soc Exp Biol Med. 1979;162(1):187–90. pmid:504229